Safety of Tralokinumab in Pediatric Patients Aged 12-17 Years With Moderate to Severe Atopic Dermatitis: Results from the Phase 3 ECZTRA 6 Trial. J of Skin 2023, 7 (2), s140. https://doi.org/10.25251/skin.7.supp.140.